MCID: DND018
MIFTS: 44

Dendritic Cell Tumor

Categories: Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Dendritic Cell Tumor

MalaCards integrated aliases for Dendritic Cell Tumor:

Name: Dendritic Cell Tumor 53
Dendritic Cell Neoplasm 53 73
Dendritic Cell Sarcoma, Not Otherwise Specified 73

Classifications:



External Ids:

Summaries for Dendritic Cell Tumor

NIH Rare Diseases : 53 A dendritic celltumor develops from the cells of the immune system.  This condition typically begins in the lymph system and may spread to nearby organs or distant parts of the body (metastasize).  There are five subtypes of dendritic cell tumors: follicular dendritic cell tumor, interdigitating dendritic cell tumor, Langerhans' cell histiocytosis, Langerhans' cell sarcoma, and dendritic cell sarcoma not specified otherwise.  The symptoms and severity of the condition depend on the subtype and location of the tumor.  Treatment may include surgery, radiation therapy, and/or chemotherapy.

MalaCards based summary : Dendritic Cell Tumor, also known as dendritic cell neoplasm, is related to leukemia, acute myeloid and histiocytic sarcoma. An important gene associated with Dendritic Cell Tumor is VIM (Vimentin), and among its related pathways/superpathways are Innate Immune System and Cytoskeletal Signaling. The drugs Central Nervous System Stimulants and Trastuzumab have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and skin, and related phenotypes are hematopoietic system and immune system

Related Diseases for Dendritic Cell Tumor

Diseases related to Dendritic Cell Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 30.2 CR1 DNTT MPO PTPRC
2 histiocytic sarcoma 30.1 CR1 CR2
3 histiocytic and dendritic cell cancer 30.1 CD207 CR1 CR2 PTPRC
4 spleen cancer 29.8 CD68 CR2
5 myeloid sarcoma 29.7 DNTT MPO PTPRC
6 renal cell carcinoma, nonpapillary 29.6 IFNG KRT20 MUC1 VIM
7 lymphoblastic lymphoma 29.6 DNTT MPO PTPRC
8 histiocytosis 29.5 CD1A CD207 PTPRC S100B
9 langerhans cell histiocytosis 29.5 CD1A CD207 IFNG S100B
10 inflammatory myofibroblastic tumor 29.5 ACTC1 CR1 CR2 S100B VIM
11 indeterminate cell histiocytosis 11.7
12 parapharyngeal meningioma 10.3 CR1 CR2
13 myeloid leukemia 10.3
14 primitive neuroectodermal tumor of the cervix uteri 10.3 PTPRC VIM
15 lymphangiectasis 10.3 ACTC1 VIM
16 multicentric reticulohistiocytosis 10.3 PTPRC VIM
17 retroperitoneal fibrosis 10.3 PTPRC VIM
18 glomangiomyoma 10.3 ACTC1 VIM
19 liver inflammatory pseudotumor 10.3 CR2 PTPRC
20 angiolipoma 10.3 ACTC1 VIM
21 intravascular papillary endothelial hyperplasia 10.3 ACTC1 VIM
22 cutaneous leiomyosarcoma 10.3 ACTC1 VIM
23 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.3 CR2 PTPRC
24 adenoid squamous cell carcinoma 10.3 KRT20 VIM
25 spindle cell lipoma 10.3 ACTC1 VIM
26 epithelioid leiomyosarcoma 10.3 ACTC1 VIM
27 malignant peritoneal mesothelioma 10.2 MUC1 VIM
28 benign metastasizing leiomyoma 10.2 ACTC1 VIM
29 papillary tumor of the pineal region 10.2 MUC1 VIM
30 secretory meningioma 10.2 MUC1 VIM
31 mast-cell sarcoma 10.2 MPO VIM
32 interdigitating dendritic cell sarcoma 10.2 CR1 CR2 PTPRC
33 ovarian lymphoma 10.2 CR2 PTPRC
34 bladder lymphoma 10.2 CR2 KRT20
35 nodular hidradenoma 10.2 MUC1 VIM
36 hidradenoma 10.2 MUC1 VIM
37 clear cell ependymoma 10.2 MUC1 VIM
38 smooth muscle tumor 10.2 ACTC1 CR2 VIM
39 primary cutaneous anaplastic large cell lymphoma 10.2 MUC1 PTPRC
40 endometrial mucinous adenocarcinoma 10.2 MUC1 VIM
41 hydromyelia 10.2 S100B VIM
42 biphasic synovial sarcoma 10.2 MUC1 VIM
43 medulloepithelioma 10.2 KRT20 VIM
44 sternum cancer 10.2 CD68 VIM
45 bednar tumor 10.2 S100B VIM
46 malignant giant cell tumor 10.2 ACTC1 S100B
47 clear cell meningioma 10.2 MUC1 VIM
48 primary hepatic neuroendocrine carcinoma 10.2 S100B VIM
49 alk+ histiocytosis 10.2 CD1A CD207 FSCN1
50 thymus lipoma 10.2 CD1A KRT20 PTPRC

Graphical network of the top 20 diseases related to Dendritic Cell Tumor:



Diseases related to Dendritic Cell Tumor

Symptoms & Phenotypes for Dendritic Cell Tumor

MGI Mouse Phenotypes related to Dendritic Cell Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 CD207 CD68 CD69 CR2 DNTT FCER2
2 immune system MP:0005387 9.36 CD207 CD68 CD69 CR2 DNTT FCER2

Drugs & Therapeutics for Dendritic Cell Tumor

Drugs for Dendritic Cell Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Central Nervous System Stimulants Phase 3
2
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
3
Adenosine Approved, Investigational Phase 2 58-61-7 60961
4
Pembrolizumab Approved Phase 2 1374853-91-4
5
Nivolumab Approved Phase 2 946414-94-4
6
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
7
Fludarabine Approved Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
8
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
9
Vidarabine Approved, Investigational Phase 2,Phase 1,Not Applicable 24356-66-9 32326 21704
10
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
11
Mycophenolic acid Approved Phase 2,Not Applicable 24280-93-1 446541
12
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 6055-19-2, 50-18-0 2907
13
leucovorin Approved Phase 2 58-05-9 6006 143
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
15
Idarubicin Approved Phase 2 58957-92-9 42890
16
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
18 Vaccines Phase 2,Phase 1,Not Applicable
19 Immunologic Factors Phase 2,Phase 1,Not Applicable
20 Antineoplastic Agents, Phytogenic Phase 2
21 Maytansine Phase 2
22 Antimitotic Agents Phase 2
23 Ado-trastuzumab emtansine Phase 2
24 Antibodies Phase 2,Phase 1
25 Immunoglobulins Phase 2,Phase 1
26 Antibodies, Monoclonal Phase 2
27 Folate Phase 2
28 Antitubercular Agents Phase 2,Not Applicable
29 Vidarabine Phosphate Phase 2,Phase 1,Not Applicable
30 Antineoplastic Agents, Alkylating Phase 2,Phase 1
31 Antiviral Agents Phase 2,Phase 1,Not Applicable
32 Vitamin B9 Phase 2
33 Calcineurin Inhibitors Phase 2,Not Applicable
34 Vitamin B Complex Phase 2
35 Antirheumatic Agents Phase 2,Phase 1,Not Applicable
36 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
37 Alkylating Agents Phase 2,Phase 1
38 Antimetabolites Phase 2,Phase 1,Not Applicable
39 Folic Acid Antagonists Phase 2
40 Immunosuppressive Agents Phase 2,Phase 1,Not Applicable
41 Anti-Bacterial Agents Phase 2,Not Applicable
42 Antibiotics, Antitubercular Phase 2,Not Applicable
43 Antimetabolites, Antineoplastic Phase 2,Phase 1,Not Applicable
44 Dermatologic Agents Phase 2,Not Applicable
45 Nucleic Acid Synthesis Inhibitors Phase 2
46 Anti-Inflammatory Agents Phase 2
47 Antineoplastic Agents, Hormonal Phase 2
48 Topoisomerase Inhibitors Phase 2
49 Gastrointestinal Agents Phase 2
50 Autonomic Agents Phase 2

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma Terminated NCT01875653 Phase 3
2 Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Unknown status NCT00085397 Phase 2
3 DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00397579 Phase 1, Phase 2 DT388IL3
4 An Open-label Phase II Study of Lorvotuzumab Mertansine Completed NCT02420873 Phase 2 Lorvotuzumab Mertansine (IMGN901)
5 SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Recruiting NCT02113982 Phase 1, Phase 2 SL-401
6 A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas Recruiting NCT03316573 Phase 2 Pembrolizumab
7 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03698994 Phase 2 Ulixertinib
8 Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting NCT03075553 Phase 2
9 Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Recruiting NCT02220985 Phase 2 Cyclophosphamide;Fludarabine Phosphate;Methotrexate;Mycophenolate Mofetil;Tacrolimus;Thiotepa
10 Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF Active, not recruiting NCT00458536 Phase 1, Phase 2 Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
11 Combination Chemotherapy in Patients With Newly Diagnosed BPDCN Not yet recruiting NCT03599960 Phase 2 Chemotherapy
12 Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Not yet recruiting NCT03739606 Phase 2
13 Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Not yet recruiting NCT03779854 Phase 2 Thiotepa;Fludarabine;Cyclophosphamide;Busulfan;Tacrolimus;Methotrexate
14 The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma Completed NCT00459069 Phase 1
15 Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy Completed NCT00700167 Phase 1
16 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
17 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting NCT03485547 Phase 1 Venetoclax
18 Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN Recruiting NCT03203369 Phase 1
19 Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm Recruiting NCT02159495 Phase 1 cyclophosphamide;Fludarabine Phosphate
20 Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies Recruiting NCT03386513 Phase 1 IMGN632
21 PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies Recruiting NCT02730312 Phase 1
22 HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Recruiting NCT03326921 Phase 1 Fludarabine Phosphate
23 Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma Active, not recruiting NCT00458653 Phase 1
24 Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Not yet recruiting NCT03807063 Phase 1 Rimiducid
25 Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) Completed NCT02859623
26 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma Active, not recruiting NCT02652715 Not Applicable
27 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies Active, not recruiting NCT00014235 Not Applicable fludarabine phosphate;cyclosporine;mycophenolate mofetil
28 Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma Terminated NCT01239875 Not Applicable

Search NIH Clinical Center for Dendritic Cell Tumor

Genetic Tests for Dendritic Cell Tumor

Anatomical Context for Dendritic Cell Tumor

MalaCards organs/tissues related to Dendritic Cell Tumor:

41
Myeloid, T Cells, Skin, Lung, Breast, Bone, Bone Marrow

Publications for Dendritic Cell Tumor

Articles related to Dendritic Cell Tumor:

(show top 50) (show all 363)
# Title Authors Year
1
First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases. ( 29720227 )
2018
2
Benefit of electron beam therapy in combination with medium-dose systemic corticosteroid as a palliative treatment for elderly patients with blastic plasmacytoid dendritic cell neoplasm: case report and review of the literature. ( 29876950 )
2018
3
Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis. ( 29705980 )
2018
4
Interdigitating dendritic cell tumor: A rare case report with review of literature. ( 29893342 )
2018
5
Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents. ( 29455234 )
2018
6
Immunophenotypic CD56 Variation Within a Single Patient With Blastic Plasmacytoid Dendritic Cell Neoplasm. ( 29490374 )
2018
7
Recurrent Indeterminate Dendritic Cell Tumor of the Skin. ( 29621879 )
2018
8
Blastic plasmacytoid dendritic cell neoplasm: a rare case of gingival lesion with leukaemic presentation. ( 29735506 )
2018
9
Clonal evolution in the transition from cutaneous disease to acute leukaemia suggested by liquid biopsy in blastic plasmacytoid dendritic cell neoplasm. ( 29419438 )
2018
10
Inflammatory pseudotumor-like follicular dendritic cell tumor of the spleen. ( 29391320 )
2018
11
Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. ( 29795241 )
2018
12
Blastic plasmacytoid dendritic cell neoplasm with centrocyte-like morphology clinically simulating a melanocytic nevus. ( 29293270 )
2018
13
Blastic plasmacytoid dendritic cell neoplasm. ( 29636962 )
2018
14
Report On Three Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. ( 29666036 )
2018
15
Atypical presentation of blastic plasmacytoid dendritic cell neoplasm: A potential diagnostic pitfall in nasal cavity. ( 29884520 )
2018
16
Exploring the effect of chidamide on blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. ( 29379294 )
2018
17
Indeterminate Dendritic Cell Tumor: A Report of 2 New Cases Lacking the ETV3-NCOA2 Translocation and a Literature Review. ( 29877893 )
2018
18
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis. ( 29080220 )
2018
19
Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations. ( 29411884 )
2018
20
An Analysis of Blastic Plasmacytoid Dendritic Cell Neoplasm with Translocations Involving the MYC Locus Identifies t(6;8)(p21;q24) as a Recurrent Cytogenetic Abnormality. ( 29884995 )
2018
21
Incidental diagnosis of blastic plasmacytoid dendritic cell neoplasm in skin excision for basal cell carcinoma. ( 30094841 )
2018
22
Skin lesions serve as clues to relapse of pediatric blastic plasmacytoid dendritic cell neoplasm. ( 29436012 )
2018
23
The distinctive cytology and disease evolution of blastic plasmacytoid dendritic cell neoplasm. ( 30020546 )
2018
24
A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm With Unusual Presentation. ( 30040070 )
2018
25
The advances in therapy of blastic plasmacytoid dendritic cell neoplasm. ( 30118336 )
2018
26
Blastic Plasmacytoid Dendritic Cell Neoplasm: Still an Enigma. ( 30127580 )
2018
27
Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis. ( 30145196 )
2018
28
Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. ( 30189324 )
2018
29
Biallelic inactivation of the retinoblastoma gene results in transformation of chronic myelomonocytic leukemia to a blastic plasmacytoid dendritic cell neoplasm: shared clonal origins of two aggressive neoplasms. ( 30190511 )
2018
30
An unexpected diagnosis: leukaemic presentation of blastic plasmacytoid dendritic cell neoplasm with massive splenomegaly. ( 30274817 )
2018
31
Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm. ( 30304659 )
2018
32
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN-Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community. ( 30338458 )
2018
33
Blastic Plasmacytoid Dendritic Cell Neoplasm. ( 30350260 )
2018
34
Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. ( 30381297 )
2018
35
Blastic plasmacytoid dendritic cell neoplasm with immunoblastoid morphology and MYC rearrangement and overexpression. ( 30482401 )
2018
36
Indeterminate dendritic cell neoplasm accompanied by eosinophilic pneumonia successfully treated by systemic steroid therapy: Report of the first case with muscular and parotid involvement and review of published work. ( 30320463 )
2018
37
Cutaneous presentation preceding acute myeloid leukemia with CD4+/CD56+ expression misdiagnosed as a blastic plasmocytoid dendritic cell neoplasm: A case report. ( 29660158 )
2018
38
Blastic Plasmocytoid Dendritic Cell Neoplasm With Skin and Myeloid Location. ( 28060117 )
2018
39
A case of disseminated blastic plasmocytoid dendritic cell neoplasm. ( 29664121 )
2018
40
Indeterminate Dendritic Cell Tumor in Thoracic Spine: A Case Report and Review of Literature. ( 28755918 )
2017
41
CD4-Negative Variant of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm With a Novel PBRM1 Mutation in an 11-Year-Old Girl. ( 28419186 )
2017
42
A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm Extensively Studied by Flow Cytometry and Immunohistochemistry. ( 28409040 )
2017
43
Blastic plasmacytoid dendritic cell neoplasm in children: A review of two cases. ( 28856005 )
2017
44
Pediatric Blastic Plasmacytoid Dendritic Cell Neoplasm: A Systematic Literature Review. ( 28906324 )
2017
45
Successful treatment with biweekly CHOP for bone marrow relapse of blastic plasmacytoid dendritic cell neoplasm. ( 28321093 )
2017
46
Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond. ( 29064022 )
2017
47
Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN. ( 29064025 )
2017
48
Blastic plasmacytoid dendritic cell neoplasm: a pathological illustration of two clinical cases. ( 28762083 )
2017
49
Recurrent MYB rearrangement in blastic plasmacytoid dendritic cell neoplasm. ( 28344318 )
2017
50
Blastic Plasmacytoid Dendritic Cell Neoplasm Presenting as Erythematous Nodules with Gallbladder Involvement. ( 28761306 )
2017

Variations for Dendritic Cell Tumor

Expression for Dendritic Cell Tumor

Search GEO for disease gene expression data for Dendritic Cell Tumor.

Pathways for Dendritic Cell Tumor

GO Terms for Dendritic Cell Tumor

Cellular components related to Dendritic Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.28 ACTC1 CR1 CR2 FCER2 FSCN1 MPO

Biological processes related to Dendritic Cell Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.56 FCER2 FSCN1 MUC1 VIM
2 intermediate filament organization GO:0045109 9.37 KRT20 VIM
3 regulation of regulatory T cell differentiation GO:0045589 9.32 CR1 IFNG
4 complement receptor mediated signaling pathway GO:0002430 9.16 CR1 CR2
5 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 8.96 FCER2 PTPRC
6 positive regulation of killing of cells of other organism GO:0051712 8.62 FCER2 IFNG

Sources for Dendritic Cell Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....